Nontuberculous Mycobacterial Infections¶
Chapter 185 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- NTM infections are increasingly common, with MAC (M. avium complex) being the most prevalent in North America, often associated with bronchiectasis and immunocompromised states.
- Diagnosis requires repeated isolation of NTM from sputum, bronchoscopy, or biopsy, with molecular techniques (DNA probes, PCR) improving speciation accuracy.
- Treatment is complex, multidrug therapy (macrolides, rifamycins, ethambutol) is standard, but resistance and toxicity pose challenges.
- Prevention includes PEP with single-dose rifampin for close contacts and prophylaxis in HIV patients with CD4+ <50/ µ L.
- Clinical manifestations vary from pulmonary disease (Lady Windermere syndrome) to cutaneous infections (M. marinum) and disseminated disease in immunocompromised hosts.
1. DEFINITION & OVERVIEW¶
Nontuberculous mycobacteria (NTM) include species other than M. tuberculosis, its relatives (M. bovis, M. africanum), and M. leprae. NTM are ubiquitous in soil and water, with over 199 identified species. The WHO promotes 'Triple Zero Strategy' (zero leprosy, zero disability, zero stigma) and PEP with single-dose rifampin to interrupt transmission.
Common NTM Species and Clinical Associations¶
| Species | Common Infections | Diagnostic Challenges |
|---|---|---|
| M. avium complex (MAC) | Pulmonary disease, disseminated in HIV | Requires repeated isolation, molecular testing |
| M. kansasii | Pulmonary disease resembling TB | May cross-react with TB tests |
| M. abscessus | Pulmonary, skin, and soft tissue infections | Rapidly growing, resistant to many antibiotics |
| M. marinum | Cutaneous infections (fish-tank granuloma) | Slow-growing, often non-acid-fast |
| M. ulcerans | Buruli ulcer (skin ulcers) | Toxin-mediated, non-acid-fast |
1.1 NTM Classification¶
NTM are categorized into rapidly growing (<7 days) and slowly growing ( ≥ 7 days) forms. Key species include M. tuberculosis complex, M. leprae, MAC (M. avium, M. intracellulare), M. kansasii, M. abscessus, M. marinum, and M. ulcerans.
1.2 WHO Guidelines¶
WHO 2018 guidelines emphasize active case-finding, contact screening, PEP with rifampin, and disability prevention. The 'Zero Leprosy' strategy targets 120 countries with zero new cases by 2030.
2. EPIDEMIOLOGY¶
NTM are ubiquitous in soil and water. Pulmonary NTM infections are more common than TB in North America, especially in elderly with bronchiectasis. Disseminated disease is rare in immunocompetent hosts but common in HIV/AIDS. Reliable incidence data are lacking due to underreporting.
NTM Incidence by Region¶
| Region | Common Species | Incidence (per 100,000) |
|---|---|---|
| North America | MAC, M. kansasii | 10–20 |
| Europe/Asia | MAC, M. abscessus, M. xenopi | 5–15 |
| Africa | M. ulcerans (Buruli ulcer), M. africanum | 1–5 |
2.1 Demographics¶
Pulmonary NTM in the U.S. is 3–10x more common than TB. MAC is most prevalent in women aged 60–70 with bronchiectasis. Cystic fibrosis patients have 3–15% NTM infection rates.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
NTM infect via inhalation, skin trauma, or hematogenous spread. Immune defects (e.g., HIV, bronchiectasis) increase susceptibility. Pathogenesis involves cytokine dysregulation (IFN- γ , TNF- α ), genetic mutations (IFNGR1, IL12RB1), and impaired granuloma formation.
Key Cytokines in NTM Pathogenesis¶
| Cytokine | Role | Deficiency Consequences |
|---|---|---|
| IFN-g | Activates macrophages, enhances granuloma formation | Disseminated MAC in HIV |
| TNF-a | Promotes inflammation, kills intracellular pathogens | Indolent NTM infections in immunocompromised |
| IL-12 | Stimulates IFN-g production | Reduced Th1 response in genetic defects |
3.1 Immune Mechanisms¶
IFN- γ and TNF- α drive granuloma formation. Defects in these pathways (e.g., GATA2 deficiency, STAT1 mutations) predispose to disseminated disease. Macrolide-resistant M. abscessus exploits host cell membrane lipid rafts.
3.2 Genetic Susceptibility¶
Mutations in IFNGR1, IL12RB1, and STAT1 cause severe NTM infections. Dominant-negative mutations in IFNGR1 lead to partial IFN- γ signaling impairment.
4. CLINICAL FEATURES¶
Pulmonary disease is most common (Lady Windermere syndrome), with chronic cough, fatigue, and nodular bronchiectasis. Cutaneous infections (M. marinum) present as painless ulcers, while disseminated disease occurs in HIV/AIDS. Cervical lymphadenopathy is common in children.
Clinical Syndromes of NTM¶
| Syndrome | Common Species | Key Features |
|---|---|---|
| Lady Windermere Syndrome | MAC | Tall, thin women with bronchiectasis |
| Cutaneous NTM | M. marinum, M. fortuitum | Painless ulcers, subcutaneous nodules |
| Disseminated Disease | MAC, M. abscessus | Systemic symptoms, organomegaly |
4.1 Pulmonary Manifestations¶
Classic 'Lady Windermere syndrome' in tall, thin women with bronchiectasis. MAC infections often present with cavitary lesions and hemoptysis. M. kansasii mimics TB with cavitary disease.
4.2 Cutaneous and Lymph Node Involvement¶
M. marinum causes 'fish-tank granuloma' with subcutaneous nodules. Cervical lymphadenopathy (MAC or M. immunogenum) is painless, often mistaken for malignancy.
5. DIFFERENTIAL DIAGNOSIS¶
Differentiate NTM from TB (similar imaging, but NTM lacks acid-fast bacilli on smear), nocardiosis (Gram-positive rods), fungal infections (e.g., histoplasmosis), and malignancy (cervical lymphadenopathy).
5.1 Imaging Findings¶
CT shows 'tree-in-bud' pattern for bronchiolar infection. Pulmonary nodules may mimic TB or malignancy. Disseminated disease requires systemic evaluation.
5.2 Laboratory Discrimination¶
NTM cultures are negative on acid-fast smears. IGRA tests may cross-react with NTM. Molecular testing (PCR, DNA probes) is essential for speciation.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires repeated isolation of NTM from sputum, bronchoscopy, or biopsy. Acid-fast smears are unreliable. Molecular techniques (PCR, DNA probes) improve speciation. IGRA tests may be indeterminate with NTM cross-reactivity.
NTM Diagnostic Algorithms¶
| Step | Test | Criteria |
|---|---|---|
| 1 | Acid-fast smear | Non-diagnostic for NTM |
| 2 | Culture | Repetitive isolation from ‡2 sources |
| 3 | Molecular testing | Species identification via PCR or DNA probes |
| 4 | IGRA | Indeterminate in NTM cross-reactivity |
6.1 Diagnostic Criteria¶
MAC infection is diagnosed with ≥ 2 positive sputum cultures, bronchoscopic samples, or biopsy. NTM must be isolated from ≥ 2 sources in compatible clinical settings.
6.2 Speciation Techniques¶
Biochemical tests, nucleic acid amplification (NAAT), and mass spectrometry (MALDI-TOF) are used. M. marinum requires special media (30°C) for growth.
7. MANAGEMENT & TREATMENT¶
Multidrug therapy (macrolides, rifamycins, ethambutol) is standard. Treatment duration is 12–24 months. Rifamycins require monitoring for drug interactions (e.g., protease inhibitors in HIV).
Standard NTM Treatment Regimens¶
| Species | First-Line Drugs | Duration |
|---|---|---|
| MAC | Clarithromycin/Rifampin/Ethambutol | 12–24 months |
| M. abscessus | Rifampin + Macrolide + Bedaquiline | 18–24 months |
| M. kansasii | Rifampin + Isoniazid + Ethambutol | 12–18 months |
7.1 Pulmonary MAC Therapy¶
Thrice-weekly macrolide (azithromycin/clarithromycin), rifampin, and ethambutol. Duration: 12–24 months. Monitor for liver toxicity and drug interactions.
7.2 Disseminated Disease¶
Rifamycins are preferred, but interactions with protease inhibitors (e.g., ritonavir) may require dose adjustments. M. abscessus requires combination therapy with bedaquiline or linezolid.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis is poor for disseminated disease in immunocompromised hosts. Complications include drug resistance, liver toxicity, and treatment failure. Early diagnosis and adherence to multidrug therapy improve outcomes.
8.1 Treatment Outcomes¶
Response to therapy is variable; 30–50% of patients may relapse. Resistance to macrolides and rifamycins is common in M. abscessus.
8.2 Long-Term Monitoring¶
Regular monitoring for drug toxicity (liver enzymes, renal function) and treatment adherence is critical. Pulmonary function tests may show progressive decline.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Avoid rifampin due to potential teratogenicity. Pediatrics: Cervical lymphadenopathy in children may be mistaken for cancer. Elderly: Higher NTM incidence due to comorbidities. HIV patients require prophylaxis (azithromycin) with CD4+ <50/ µ L.
NTM Prophylaxis Guidelines¶
| Population | Prophylaxis | CD4+ Threshold |
|---|---|---|
| HIV patients | Azithromycin 1200 mg weekly | <50/mL |
| Immunocompromised | Rifampin or Macrolides | Defects in IFN-g/IL-12 pathway |
| Close contacts | Single-dose Rifampin PEP | High-risk populations |
9.1 Genetic Defects¶
GATA2 deficiency increases risk of disseminated NTM. Genetic testing is recommended for recurrent infections in immunocompromised patients.
9.2 PEP Implementation¶
Single-dose rifampin PEP reduces leprosy risk by ~60%. Widespread use is critical for WHO's 'Zero Leprosy' goals.
10. KEY POINTS & CLINICAL PEARLS¶
- NTM infections are increasingly common, especially in immunocompromised hosts. 2. Diagnosis requires repeated isolation and molecular testing. 3. Multidrug therapy is essential, but resistance and toxicity are challenges. 4. PEP with rifampin is critical for preventing leprosy transmission. 5. Disseminated disease in HIV requires careful management of drug interactions.